{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:06:22Z","timestamp":1791648382964,"version":"4.3.4"},"reference-count":30,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"unspecified","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2024,3,3]]},"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>There is a paucity of data on long-term clinical responses in patients with non-radiographic axial spondyloarthritis (nr-axSpA) based on their baseline objective signs of inflammation such as MRI or C-reactive protein (CRP) levels. This study reports clinical outcomes up to 3 years of the C-axSpAnd trial, including safety follow-up extension (SFE) from Weeks 52 to 156, stratified by patients\u2019 baseline MRI and CRP status.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>C-axSpAnd (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02552212\">NCT02552212<\/jats:ext-link>) was a phase 3, multicentre study that evaluated certolizumab pegol (CZP) in patients with active nr-axSpA who had active sacroiliitis on MRI and\/or elevated CRP. In this post hoc analysis, efficacy outcomes are reported to Week 156 of C-axSpAnd for patients stratified according to their MRI and CRP status at Week 0 (MRI+\/CRP\u2212, MRI\u2212\/CRP+ and MRI+\/CRP+).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Across all outcome measures, including major improvement in Ankylosing Spondylitis Disease Activity Score (ASDAS-MI) and Assessment of SpondyloArthritis international Society criteria \u226540% response (ASAS40), outcomes were generally sustained in SFE patients from Week 52 to Week 156. MRI+\/CRP+ patients showed numerically higher or comparable responses relative to MRI\u2212\/CRP+ and MRI+\/CRP\u2212 patients at Weeks 52 and 156; however, all three subgroups demonstrated substantial improvements from Week 0 (in CZP-randomised patients, ASDAS-MI at Week 156 [observed case]: MRI+\/CRP+: 73.1%, MRI\u2013\/CRP+: 52.2%, MRI+\/CRP\u2013: 30.4%; ASAS40: MRI+\/CRP+: 76.9%, MRI\u2013\/CRP+: 62.5%, MRI+\/CRP\u2013: 65.2%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In patients with nr-axSpA and objective signs of inflammation, long-term clinical outcomes achieved after 1 year were generally sustained at 3 years across MRI+\/CRP+, MRI\u2212\/CRP+ and MRI+\/CRP\u2212 subgroups.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2023-003884","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T13:20:47Z","timestamp":1715260847000},"page":"e003884","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct02552212","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02552212","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02552212","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02552212","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5445-548X","authenticated-orcid":false,"given":"Martin","family":"Rudwaleit","sequence":"first","affiliation":[{"name":"Klinikum Bielefeld, University of Bielefeld, Bielefeld, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Bauer","sequence":"additional","affiliation":[{"name":"UCB Pharma, Monheim am Rhein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianne","family":"Gensler","sequence":"additional","affiliation":[{"name":"University of California, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Hoepken","sequence":"additional","affiliation":[{"name":"UCB Pharma, Monheim am Rhein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kumke","sequence":"additional","affiliation":[{"name":"UCB Pharma, Monheim am Rhein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone Emanuele","family":"Auteri","sequence":"additional","affiliation":[{"name":"UCB Pharma, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindy","family":"Kim","sequence":"additional","affiliation":[{"name":"UCB Pharma, Smyrna, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1291-1755","authenticated-orcid":false,"given":"Walter","family":"Maksymowych","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,5,9]]},"reference":[{"issue":"Suppl 1","key":"2025090312374839000_10.2.e003884.1","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000053","article-title":"Non-radiographic axial spondyloarthritis and ankylosing spondylitis: what are the similarities and differences","volume":"1","author":"Baraliakos","year":"2015","journal-title":"RMD Open"},{"key":"2025090312374839000_10.2.e003884.2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24483"},{"key":"2025090312374839000_10.2.e003884.3","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223298"},{"key":"2025090312374839000_10.2.e003884.4","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/acr.22848","article-title":"Observed incidence of uveitis following certolizumab pegol treatment in patients with axial spondyloarthritis","volume":"68","author":"Rudwaleit","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312374839000_10.2.e003884.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.4182"},{"key":"2025090312374839000_10.2.e003884.6","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s40744-020-00214-7","article-title":"Induction of sustained clinical remission in early axial spondyloarthritis following certolizumab pegol treatment: 48-week outcomes from C-OPTIMISE","volume":"7","author":"Landew\u00e9","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2025090312374839000_10.2.e003884.7","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/rmdopen-2019-001161","article-title":"The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW","volume":"6","author":"van der Horst-Bruinsma","year":"2020","journal-title":"RMD Open"},{"key":"2025090312374839000_10.2.e003884.8","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211003803","article-title":"Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study","volume":"13","author":"van der Horst-Bruinsma","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2025090312374839000_10.2.e003884.9","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/rheumatology\/kex174","article-title":"Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA","volume":"56","author":"van der Heijde","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312374839000_10.2.e003884.10","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/art.40866","article-title":"A fifty-two-week, randomized, placebo-controlled trial of certolizumab pegol in nonradiographic axial spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025090312374839000_10.2.e003884.11","unstructured":"CIMZIA (certolizumab pegol) . Product information: UCB, Inc. Smyrna, GA, USA: Administration FaD, Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125160s237lbl.Pdf"},{"key":"2025090312374839000_10.2.e003884.12","unstructured":"European Medicines Agency . CIMZIA. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cimzia [Accessed 8 Mar 2023]."},{"key":"2025090312374839000_10.2.e003884.13","doi-asserted-by":"crossref","DOI":"10.1186\/ar3369","article-title":"Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in Ankylosing Spondylitis: a prospective longitudinal observational cohort study","volume":"13","author":"Arends","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2025090312374839000_10.2.e003884.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201766"},{"key":"2025090312374839000_10.2.e003884.15","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1002\/art.39257","article-title":"A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis","volume":"67","author":"Sieper","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025090312374839000_10.2.e003884.16","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-000917","article-title":"Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study","volume":"5","author":"Sieper","year":"2019","journal-title":"RMD Open"},{"key":"2025090312374839000_10.2.e003884.17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211313"},{"key":"2025090312374839000_10.2.e003884.18","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.073098"},{"key":"2025090312374839000_10.2.e003884.19","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.145995"},{"key":"2025090312374839000_10.2.e003884.20","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/s13075-021-02650-4","article-title":"Predictors of long-term clinical response in patients with non-radiographic axial Spondyloarthritis receiving Certolizumab Pegol","volume":"23","author":"Maksymowych","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2025090312374839000_10.2.e003884.21","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/acr2.11469","article-title":"Certolizumab pegol efficacy in patients with non-radiographic axial spondyloarthritis stratified by baseline MRI and C-reactive protein status: an analysis from the C-axSpAnd study","volume":"4","author":"Robinson","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"2025090312374839000_10.2.e003884.22","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"Update of the American college of rheumatology\/Spondylitis Association of America\/Spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025090312374839000_10.2.e003884.23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210770"},{"key":"2025090312374839000_10.2.e003884.24","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.133645"},{"key":"2025090312374839000_10.2.e003884.25","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"2025090312374839000_10.2.e003884.26","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"2025090312374839000_10.2.e003884.27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208642"},{"key":"2025090312374839000_10.2.e003884.28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/rmdopen-2021-002138","article-title":"Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study","volume":"8","author":"van der Heijde","year":"2022","journal-title":"RMD Open"},{"key":"2025090312374839000_10.2.e003884.29","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/art.38721","article-title":"Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"66","author":"Dougados","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025090312374839000_10.2.e003884.30","first-page":"S47","article-title":"Measures of symptoms and disease status in Ankylosing Spondylitis: Ankylosing Spondylitis disease activity score (ASDAS), Ankylosing Spondylitis quality of life scale (Asqol), Bath Ankylosing Spondylitis disease activity index (BASDAI), Bath Ankylosing Spondylitis functional index (BASFI), Bath Ankylosing Spondylitis global score (BAS-G), Bath Ankylosing Spondylitis Metrology index (BASMI), Dougados functional index (DFI), and health Assessment7 questionnaire for the Spondylarthropathies (HAQ-S)","volume":"63 Suppl 11","author":"Zochling","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2023-003884","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:37:56Z","timestamp":1756928276000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2023-003884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,5,9]]},"published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1136\/rmdopen-2023-003884"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2023-003884","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5]]}}}